Among the highest-valued personal business in biotech is lastly going public.

Moderna Rehabs is anticipated to begin trading Friday, after pricing Thursday at $23 a share. The business is offering approximately 27 million shares, valuing the business at about $7.5 billion. In overall, the business is raising $620 million in the offering, making it the greatest going public in biotech history.

Moderna is establishing medical treatments based upon messenger RNA, and the business is still in the early days of human trials for its treatments, that include cancer treatments in addition to a vaccine for cytomegalovirus, or CMV.

In early November, Moderna submitted with the United States Securities and Exchange Commission to go public, and it will trade under the ticker MRNA.

Learn More: The marketplace for biotech IPOs is red hot– here are the top 10 of 2018

It’s been a huge year for biotech IPOs. In October, early-stage cancer biotech Allogene ended up being the then-biggest biotech ever. It raised $324 million in an IPO that valued the business at more than $2 billion.

Leaving Out Moderna, there have actually been 56 biotech IPOs that have actually raised an overall $5.5 billion in 2018, according to Renaissance Capital. It’s the greatest overall given that 2014, when there were 71 biotech IPOs that raised a combined $5.2 billion.